Nur Kir

Nur Kir

Auto-generated profile, based on publicly available information

Nur Kir

Department of Ophthalmology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2021 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
NANihan Aksu-Ceylan
Nihan Aksu-Ceylan
ZCZafer Cebeci
Zafer Cebeci
EAEmre Altinkurt
Emre Altinkurt
NKNur Kir
Nur Kir
MOMerih Oray
Merih Oray
ITIlknur Tugal-Tutkun
Ilknur Tugal-Tutkun
To report the results of interferon (IFN) α-2a treatment in patients with cystoid macular edema (CME) secondary to acute retinal necrosis (ARN).We reviewed the records of seven patients (eight eyes...

1 June 2019 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
AUAdem Uğurlu
Adem Uğurlu
MAMaisa Aslanova
Maisa Aslanova
ZCZafer Cebeci
Zafer Cebeci
NMNur Kır Mercül
Nur Kır Mercül
To determine length of hydroxychloroquine use and cumulative dose and evaluate the ocular effects by 10-2 central visual field test, microperimetry (MP), color fundus photography, optical coherence tomography (OCT), and fundus autofluorescence (FAF) in hydroxychloroquine users. Patients who used hydroxychloroquine continuously for at least 2 years for various connective tissue diseases were included in the study. A total of 300 eyes of 150 patients aged 19-78 years who were followed due to risk of developing hydroxychloroquine maculopathy in the İstanbul University İstanbul Faculty of Medicine Ophthalmology Department between the years 1995-2017 were evaluated. Best corrected visual acuity (BCVA), biomicroscopic, and fundoscopic examination were performed at all visits. MP, FAF, OCT, fundus photography, and central 10-2 visual field examinations were performed 3 times at 6-month intervals. The mean age of patients was 48.9±10.8 years; 141 (94%) patients were female and 9 (6%) were male. The mean duration of hydroxychloroquine use was 10.5±6.4 (2-30) years. Fifty-six patients had been using the drug for 5 years or less. The mean cumulative drug dose was 754.7±447.2 (146-1825) g. Mean BCVA was 0.02±0.08 LogMAR at all follow-up visits (p=0.999). Mean MP values at the first, second, and third examinations were 14.07±3.24 dB, 14.18±3.35 dB, and 14.54±2.79 dB, respectively (p>0.05). Mean central macular thickness was 221.9±19.8 µm at initial examination, 221.8±19.9 µm at the second visit, and 221.8±19.8 µm at the final visit (p=0.113). There was a weak negative correlation between age and MP values at all three visits (visit 1: p=0.003, r=- 0.170; visit 2: p=0.001, r=-0.185, visit 3: p=0.011, r=-0.146). There was statistically significant relationship between MP values and hydroxychloroquine length of use and cumulative dose (p=0.027 and p=0.049, respectively). Duration of use was not associated with changes in 10/2 visual field (p=0.124). There were significant relationships between alterations in FAF and hydroxychloroquine length of use and cumulative dose (p=0.027 and p=0.049, respectively). FAF alterations were significantly associated with duration of hydroxychloroquine use and cumulative dose. As objective methods are more reliable, examinations such as FAF can be recommended as auxiliary methods in the follow-up and early detection of toxic maculopathy.

1 December 2022 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
NANihan Aksu-Ceylan
Nihan Aksu-Ceylan
MGMehmet Eren Güner
Mehmet Eren Güner
ZCZafer Cebeci
Zafer Cebeci
EAEmre Altınkurt
Emre Altınkurt
NKNur Kır
Nur Kır
ITIlknur Tugal-Tutkun
Ilknur Tugal-Tutkun
Objectives: The aims of this study were to describe the clinical presentation and treatment modalities of acute retinal necrosis (ARN) and to evaluate complications and clinical outcomes according to the extent of retinal involvement at initial presentation. Materials and Methods: The medical records of 52 patients diagnosed with ARN were reviewed and 48 were included in the study. Patients were categorized into two groups according to the extent of retinitis at presentation: retinal involvement of 1-2 quadrants (Group A) or 3-4 quadrants (Group B). Results: The mean age of the 14 women and 34 men at presentation was 51.3 +/- 13.6 years (range: 27-78). There were 40 unilateral and 8 bilateral cases. There were 11 eyes (19.6%) in Group A and 45 eyes (80.4%) in Group B. Eleven patients (22.9%) had a history of herpes simplex virus/varicella-zoster virus infection. One patient in Group A and 11 patients in Group B had received local or systemic corticosteroid therapy without concomitant antiviral treatment before referral. The median follow-up period was 29 months (range: 1-209) in Group A and 8.5 months (range: 0.75-209) in Group B. Mean visual acuity (VA) at presentation was 0.42 +/- 0.55 LogMAR (range: 0-2.0) in Group A and 1.28 +/- 0.95 LogMAR (range: 0-2.9) in Group B (p<0.05). The presence of endothelial keratic precipitates at presentation was significantly different between two groups (p=0.021). Retinal detachment (RD) occurred in 1 eye (9.1%) in Group A and 30 eyes (66.7%) in Group B (p<0.001). Optic disc pallor was seen in 36.4% (4/11) of eyes in Group A and 71.1% (32/45) of eyes in Group B (p=0.033). Other ocular complications were not significantly different between two groups. Mean final visual acuity was 0.29 +/- 0.41 LogMAR in Group A and 1.61 +/- 0.90 LogMAR in Group B (p<0.05). Conclusion: The extent of retinal involvement at presentation affects visual outcomes and this shows the importance of early diagnosis and early initiation of antiviral treatment.

1 July 2025 in International Ophthalmology
Verified
Journal Article
Open access
PDF file
FCFeyza Cukurova
Feyza Cukurova
BIBelgin Izgi
Belgin Izgi
ZCZafer Cebeci
Zafer Cebeci
NKNur Kir
Nur Kir
Aim To report real-life data of eyes with neovascular age-related macular degeneration (nAMD) treated with vascular endothelial growth factor (VEGF) inhibitors for an average of 10 years. Methods Anti-VEGF naïve eyes with nAMD and had at least 7-year follow-up at a tertiary center were evaluated. The primary outcome was a change in best-corrected visual acuity (BCVA) at 10 years; secondary outcomes included anatomical outcomes, number of injections, and examinations. Results The study included 102 eyes of 82 patients, with a mean initial age of 69.2 ± 9.7 years. The average follow-up duration was 116.19 ± 24.98 months, and the mean number of injections was 37.42 ± 15.81. Initial mean BCVA was 59.0 ± 18.3 letters, increasing to 70.55 ± 12.72 in the first year, then gradually declining to 60.44 ± 17.55 by the tenth year. Patients had an average of 6.13 ± 1.72 exams in the first year and 4.61 ± 2.60 in the last year, with 6.02 ± 1.70 injections in the first year and 3.18 ± 2.17 in the tenth year. Patients were classified as increasing, decreasing, or stable based on changes in VA by 2 lines or 10 letters. Significant variables among the groups included age (p = 0.018), baseline BCVA (p = 0.001), prior photodynamic therapy (PDT) (p = 0.025), and retinal hemorrhage due to macular neovascularization (MNV) (p = 0.049). Conclusion Eyes with nAMD maintained their initial BCVA after treatment with VEGF inhibitors for 10 years. With regular and prompt treatment, functional vision can be achieved over a long period of time in nAMD.